INCB161734 + Chemotherapy for Pancreatic Cancer

(DAWN-303 Trial)

This trial tests how well a new drug, INCB161734 (an experimental treatment), works with standard chemotherapy in treating metastatic pancreatic ductal adenocarcinoma (PDAC), a type of advanced pancreatic cancer. Researchers aim to determine if adding this drug improves the treatment's effectiveness and safety. The trial includes two groups: one receiving INCB161734 with chemotherapy and another receiving a placebo with chemotherapy. Individuals diagnosed with metastatic PDAC and a KRAS G12D mutation, who have not received prior treatment for their cancer, might be suitable candidates. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to a treatment that could soon become widely available.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that INCB161734 is generally safe. In earlier studies, patients who received this treatment alone or with other cancer therapies usually tolerated it well. These studies focus on its use for cancers with a specific mutation called KRAS G12D. The results consistently indicate that the side effects are manageable. Although any treatment can have side effects, current data suggest that INCB161734 is safe enough for further testing in more advanced trials.¹²³⁴⁵

Researchers are excited about INCB161734 because it offers a new approach to treating pancreatic cancer by combining with standard chemotherapy options like mFOLFIRINOX or GemNabP. Unlike traditional treatments that primarily focus on directly attacking cancer cells, INCB161734 could potentially enhance the effectiveness of chemotherapy by targeting specific pathways in the cancer cells. This innovative mechanism may help improve patient outcomes by making the cancer cells more susceptible to the effects of chemotherapy, offering hope for better control of the disease.

Research has shown that INCB161734 may be promising for treating pancreatic cancer. In patients with pancreatic ductal adenocarcinoma (PDAC), those taking 1,200 mg of INCB161734 daily had a 34% chance of significant tumor shrinkage. Among a group of 41 patients, 37% experienced a reduction in tumor size, and in 78% of cases, the cancer did not worsen. In this trial, one group of participants will receive INCB161734 with standard chemotherapy, while another group will receive a placebo with standard chemotherapy. These findings suggest that INCB161734, when combined with standard chemotherapy, might manage the disease better than chemotherapy alone.¹⁴⁵⁶⁷